CD40LG and ovarian carcinoma: Recently, agonist anti-CD40 antibody and CD40L alone or in combination with other therapies have been shown to significantly reduce the growth of B cell lymphomas, breast and ovarian carcinomas, and several other solid tumors and prolong overall survival of patients [80].